TRIDENT LIFELINE
|
The Current P/E Ratio of TRIDENT LIFELINE is 35.45.
| Share Price | ₹298.0 | Oct 27,2025 |
| Market Cap | ₹345.7 Cr | |
| Earnings-TTM | ₹9.8 Cr | TTM-Consolidated Results |
| Price/Earnings | 35.45x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of TRIDENT LIFELINE
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹345.7 Cr] as on Oct 27,2025
(/) Earnings [ ₹9.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 35.45x ]
Thus, for TRIDENT LIFELINE , the investors are currently willing to pay 35.45 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of TRIDENT LIFELINE !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of TRIDENT LIFELINE over the last five years.
Historical PE (Price/Earnings) ratio chart of TRIDENT LIFELINE
PE Ratio Performance Analysis for TRIDENT LIFELINE
- TRIDENT LIFELINE 's p/e ratio for fiscal years ending Mar2024 to Mar2022 averaged 20.04x.
- TRIDENT LIFELINE 's operated at median p/e ratio of 29.71x from fiscal years ending March 2018 to 2022.
- Looking back at the last 3 fiscal years, TRIDENT LIFELINE 's p/e ratio peaked in Mar2023 at 30.41x.
- TRIDENT LIFELINE 's p/e ratio hit its five-year low in Mar2022 of 0x.
How does TRIDENT LIFELINE 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| TRIDENT LIFELINE | 9.75 | 35.45 | 345.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,411.50 | 39.04 | 406,471.0 |
| DIVIS LABORATORIES LTD | 2,306.00 | 74.72 | 172,294.0 |
| CIPLA LTD | 5,406.81 | 23.66 | 127,946.0 |
| TORRENT PHARMACEUTICALS LTD | 2,002.00 | 60.78 | 121,691.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.74 | 107,214.0 |
| MANKIND PHARMA LTD | 1,905.51 | 52.31 | 99,677.0 |
| ZYDUS LIFESCIENCES LTD | 4,637.80 | 22.00 | 102,017.0 |
| LUPIN LTD | 3,722.18 | 23.59 | 87,812.2 |
| AUROBINDO PHARMA LTD | 3,417.93 | 18.60 | 63,589.1 |
| ABBOTT INDIA LTD | 1,452.29 | 43.57 | 63,282.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs TRIDENT LIFELINE 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.60x |
| Max industry PE | 74.72x |
| Median industry PE | 35.45x |
| Average industry PE | 37.50x |
You may also like the below Video Courses